drugset / Trial / NCT02348619

"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

NCT02348619

Phase 3 Completed 174 enrolled Jazz Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is a 6-week, double-blind, placebo-controlled, randomized-withdrawal, multicenter study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.

Timeline

Start
2015-05
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Solriamfetol Small molecule 75 mg
Comparator Solriamfetol Small molecule 150 mg
Comparator Solriamfetol Small molecule 300 mg